Prataap Snacks grants 50,906 ESARs to employees under 2018 plan
Prataap Snacks Limited has granted 50,906 Employee Stock Appreciation Rights (ESARs) to eligible employees under its Prataap Employees Stock Appreciation Rights Plan 2018. Approved by the Nomination and Remuneration Committee on August 1, 2026, the grant sets the price per ESAR at Rs. 1,159 with a face value of Rs. 5 per share. The move supports long-term employee retention and alignment with shareholder value, while historical data shows significant lapses in previous grants, highlighting strict vesting criteria.

*this image is generated using AI for illustrative purposes only.
Prataap Snacks has granted 50,906 Employee Stock Appreciation Rights (ESARs) to eligible employees under its Prataap Employees Stock Appreciation Rights Plan 2018. The Nomination and Remuneration Committee approved the grant during its meeting on August 1, 2026, continuing the firm’s equity-based compensation strategy designed to align employee interests with long-term shareholder value. This move reinforces retention efforts by offering financial upside linked to the company’s stock performance.
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III thereof. The scheme complies with the SEBI (Share Based Employee Benefits) Regulations, 2021, and follows the framework outlined in SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. Company Secretary Sanjay Chourey confirmed that the requisite details have been submitted to both the National Stock Exchange of India Limited and BSE Limited for record purposes.
Key Details of the ESAR Grant
The financial and structural parameters of the newly granted ESARs are outlined below:
| Metric | Details |
|---|---|
| Number of ESARs Granted | 50,906 |
| Price per ESAR | Rs. 1,159 |
| Face Value per Share | Rs. 5 |
| Vesting Period | Minimum one year, maximum five years |
| Exercise Window | Up to three years from vesting date |
Upon exercise, the number of shares allotted will be determined by the formula: (Appreciation per ESAR x Number of ESARs exercised) / Market Price with reference to the date of exercise. Grantees are required to pay the face value of the shares prevailing at the time of allotment.
Plan Status and Historical Adjustments
As of the grant date, the total number of ESARs vested under the plan stands at 4,40,701. Of these, 1,41,329 ESARs have been exercised, resulting in the allotment of 50,935 shares. The company realized proceeds of Rs. 2,54,675 from these exercises. Conversely, 3,17,725 ESARs have lapsed due to non-exercise within the stipulated timeframes.
The Nomination and Remuneration Committee has previously adjusted exercise periods to benefit grantees. In a meeting on August 2, 2023, the committee extended the exercise period by two years for 3,47,000 ESARs granted on August 9, 2019, covering vesting dates up to August 8, 2025, and August 8, 2026. Most recently, on August 1, 2026, the committee extended the exercise period by two years for 1,02,716 ESARs granted on August 19, 2022, pushing the first vesting deadline to August 18, 2028.
What the Numbers Show
The dilution impact of the plan remains contained, with diluted earnings per share calculated at Rs. 1.03 following the issue of equity shares upon exercise. The significant number of lapsed ESARs (3,17,725) suggests that a portion of the initial pool did not meet vesting conditions or was not exercised within the window, indicating strict adherence to performance or tenure-based criteria. The recent extensions granted by the committee reflect a flexible approach to retention, allowing employees additional time to realize the value of their awards amidst market volatility.
Historical Stock Returns for Prataap Snacks
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.91% | -0.86% | -0.37% | +7.45% | +24.65% | +75.92% |
How might the recent two-year extension of the exercise window for 2022-granted ESARs impact future employee retention rates and stock price volatility upon eventual exercise?
Given the high lapse rate of over 317,000 ESARs, what specific performance or tenure criteria are likely driving non-exercise, and will the company adjust vesting conditions for future grants?
What is the projected dilution effect on earnings per share if the current outstanding ESARs are fully exercised at the upper end of the three-year exercise window?


































